And four other potential targets that could make sense for the beleaguered group.
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.